The study is being conducted to compare the pharmacokinetics and safety of HRS-7535 in subjects with mild to moderate hepatic impairment and normal hepatic function.

开始日期2025-06-05

申办/合作机构

山东盛迪医药有限公司

NCT06904105

/ Active, not recruiting临床3期

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HRS-7535 Tablets in Subjects With Overweight or Obesity

The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.

开始日期2025-04-09

申办/合作机构

山东盛迪医药有限公司

NCT06820099

/ Recruiting临床2期

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS-7535 in Subjects With Heart Failure With Preserved Ejection Fraction and Obesity

This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 40-weeks' treatment period, and a 1-week safety follow-up visit period.

开始日期2025-03-31

申办/合作机构

山东盛迪医药有限公司

100 项与 HRS-7535 相关的临床结果

登录后查看更多信息

100 项与 HRS-7535 相关的转化医学

登录后查看更多信息

100 项与 HRS-7535 相关的专利（医药）

登录后查看更多信息

项与 HRS-7535 相关的文献（医药）

2024-03-01·Diabetes, obesity & metabolism

Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial

Article

作者: Zhou, Renpeng ; Shu, Chang ; Wang, Quanren ; Fan, Yang ; Ye, Zi ; Zhang, Qian ; Qin, Huiling ; Du, Yijun ; Shen, Yu ; Feng, Sheng ; Zhang, Qin ; Hu, Wei ; Wu, Jingying ; Xu, Yimei

Abstract:

Aim:

To assess the safety, tolerability, pharmacokinetics (PKs) and pharmacodynamics of HRS‐7535, a novel glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), in healthy participants.

Materials and Methods:

This phase 1 trial consisted of single‐ascending dose (SAD), food effect (FE) and multiple‐ascending dose (MAD) parts. In the SAD part, participants were randomized (6:2) to receive HRS‐7535 (at doses of 15, 60 and 120 mg; administered orally once daily) or placebo. In the FE part, participants were randomized (8:2) to receive a single dose of 90‐mg HRS‐7535 or placebo, in both fed and fasted states. In the MAD part, participants were randomized (18:6) to receive daily HRS‐7535 (120 mg [30/60/90/120‐mg titration scheme]) or placebo for 28 days. The primary endpoints were safety and tolerability.

Results:

Nausea and vomiting were the most frequently reported AEs across all three parts. In the SAD part, the median Tmax was 5.98‐5.99 hours and the geometric mean t1/2 was 5.28‐9.08 hours across the HRS‐7535 dosing range. In the MAD part, the median Tmax was 5.98‐10.98 hours and the geometric mean t1/2 was 6.48‐8.42 hours on day 28 in participants on HRS‐7535. PKs were approximately dose‐proportional. On day 29 in the MAD part, the mean (percentage) reduction in body weight from baseline was 4.38 kg (6.63%) for participants who received HRS‐7535, compared with 0.8 kg (1.18%) for those participants who received a placebo.

Conclusions:

HRS‐7535 exhibited a safety and tolerability profile consistent with other GLP‐1RAs and showed PKs suitable for once‐daily dosing. These findings support further clinical development of HRS‐7535 for type 2 diabetes.

161

项与 HRS-7535 相关的新闻（医药）

2025-09-05

·PRNewswire

Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893

Collaboration highlights Hengrui Pharma's successful use of the NewCo model to achieve another out-licensing deal Agreement grants Braveheart Bio exclusive global rights to develop, manufacture and commercialize HRS-1893 outside of Mainland China, the Hong Kong SAR, the Macao SAR and Taiwan Region HRS-1893 currently in Phase 3 clinical trial in China for treatment of obstructive hypertrophic cardiomyopathy (oHCM) SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH；01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential. Braveheart Bio is a newly launched, U.S.-based biotechnology company focused on cardiovascular disease with a consortium of lead investors that includes Forbion, OrbiMed, and others. Under the terms of the agreement, Hengrui Pharma has granted Braveheart exclusive rights to develop, manufacture and commercialize HRS-1893 worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, and Taiwan Region. Braveheart will make an upfront payment of $65 million (consisting of $32.5 million in cash and $32.5 million in Braveheart shares) and a near-term payment of up to $10 million upon technology transfer completion, totaling $75 million. Hengrui Pharma is eligible to receive potential development and commercial milestone payments of up to $1.013 billion, in addition to related royalties based on the net sales. "This marks the second time in less than 18 months that Hengrui Pharma has partnered with leading international investment institutions and leveraged the NewCo model in our efforts to ensure our innovation benefits patients worldwide," said Frank Jiang, MD, PhD, Executive Vice President and Chief Strategy Officer of Hengrui Pharma. "This agreement demonstrates the global competitiveness of our diversified, high-value R&D pipeline, and will accelerate the development of our innovative therapies for cardiovascular diseases, bringing more clinically valuable treatment options to patients around the world." "We're excited to partner with Hengrui to advance HRS-1893 into late-stage clinical development," said Braveheart Bio CEO Travis Murdoch, MD. "The recently presented Phase 1 data on HRS-1893 at ESC 2025 support our conviction in this molecule. We believe that it may confer best-in-class properties among cardiac myosin inhibitors. We are looking forward to further advancing its potential as a differentiated therapeutic for large and growing unmet needs in cardiovascular disease." In May 2024, Hengrui Pharma completed a landmark deal leveraging the NewCo model, out-licensing its portfolio of innovative GLP-1 class drugs (HRS-7535, HRS9531, HRS-4729) to Kailera Therapeutics, a newly established U.S.-based company backed by prominent investment institutions including Bain Capital Life Sciences, Atlas Venture, and RTW Investments, of which the total deal value, comprising upfront and milestone payments, could reach up to $6 billion; Hengrui also acquired a 19.9% equity stake in the new company. HRS-1893 is one of Hengrui Pharma's key innovative achievements in the heart disease space and recently entered Phase 3 clinical trials. Currently, the company has more than 10 innovative products in the cardiovascular disease field that have advanced to clinical research or beyond. Hengrui Pharma is also progressing investigational candidates for the treatment of heart disease, including SHR-6934, SHR-4658 and HRS-9057 in heart failure-related clinical studies. About Hypertrophic Cardiomyopathy (HCM) Hypertrophic cardiomyopathy (HCM), a primary cardiomyopathy characterized by left ventricular hypertrophy, is the most common genetic heart disease and the primary cause of sudden cardiac death in adolescents and athletes1,2. HCM is classified into obstructive HCM (oHCM) and non-obstructive HCM (nHCM) depending on whether the peak pressure difference of the left ventricular outflow tract at rest or after excitation are both less than 30mmHg1. Compared to patients with nHCM, those with oHCM have a lower survival rate. Relieving obstruction helps to reduce the risk of death. About HRS-1893 HRS-1893 is a highly selective small molecular myosin inhibitor independently developed by Hengrui that can specifically inhibit the activity of myosin ATPase, inhibit myocardial excessive contraction, reduce left ventricular hypertrophy and improve diastolic compliance. Multiple clinical trials for HRS-1893 have been conducted, with Phase 1 data recently presented at the European Society of Cardiology (ESC) Congress 2025. A phase 3 trial in oHCM has been initiated. About Hengrui Pharma Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. About Braveheart Bio Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies for cardiovascular disease. Braveheart is backed by world-class life science investors including Forbion and OrbiMed. Forbion is a leading European life sciences firm, active across stages and focused on bringing paradigm shifting innovation in medicine to patients around the globe. In addition, its newly-raised BioEconomy fund invests in planetary health solutions, "feeding and cleaning the planet." OrbiMed is one of the world's leading investors in healthcare, managing approximately $17 billion and aiming to help build world-class public and private healthcare companies. Reference: The Cardiomyopathy Specialty Alliance of National Center for Cardiovascular Diseases, Cardiovascular Precision Medicine Branch of China International Exchange and Promotive Association for Medical and Health Care. 2025 Chinese Guideline for the Management of Cardiomyopathies. Chinese Circulation Journal. 2025, 40 (5): 420-462. Zhaoxu Jia, Xin Du. Risk Assessment and Treatment of Sudden Death in Hypertrophic Cardiomyopathy. Journal of Clinical Internal Medicine. 2024, 41 (6): 370-374. SOURCE Jiangsu Hengrui Pharmaceuticals Co., Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期引进/卖出临床3期

2025-09-05

·医药地理

10.88亿美元！恒瑞NewCo出海再下一城

9月5日，恒瑞医药宣布就其自主研发的心肌肌球蛋白（Myosin）小分子抑制剂HRS-1893与美国Braveheart Bio达成全球独家许可协议。此次交易采用的“NewCo”模式，通常指许可方将创新药项目授权给由境外资本或跨国药企共同新设的海外公司，以获取许可费及股权，并整合双方优势推进管线的开发与商业化。这是恒瑞继去年5月将GLP-1类创新药组合（HRS-7535、HRS9531、HRS-4729）有偿许可给Hercules后，再次采用NewCo模式实现对外授权。根据协议条款，恒瑞医药将HRS-1893在除中国大陆、香港特别行政区、澳门特别行政区及台湾地区以外的全球范围内开发、生产和商业化的独家权利有偿许可给Braveheart Bio。Braveheart Bio将向恒瑞医药支付6500万美元首付款（含3250万美元现金和等值3250万美元的Braveheart Bio公司股权）和完成技术转移后的1000万美元近期里程碑款，总计7500万美元。此外，恒瑞医药还将收取最高可达10.13亿美元的与临床开发和销售相关的里程碑付款，及相应的销售提成。恒瑞医药执行副总裁、首席战略官江宁军博士表示：“这是恒瑞再度携手国际资本，以NewCo模式推动全球医药创新。此次成功引入Forbion资本、OrbiMed等全球顶尖生命科学投资机构，不仅彰显了恒瑞多元化、高价值研发管线的国际竞争力，也将加速我们在心脏病领域创新疗法的全球开发进程，为全球患者提供更具临床价值的治疗新选择。” Braveheart Bio首席执行官Travis Murdoch医学博士表示：“我们非常高兴与恒瑞医药携手，推动HRS-1893进入后期临床开发阶段。近期在2025年欧洲心脏病学会（ESC）大会上公布的HRS-1893的Ⅰ期研究数据，进一步坚定了我们对该分子的信心，我们相信HRS-1893具备心肌肌球蛋白抑制剂同类最佳的潜质。心血管疾病领域存在大量且持续增长的未被满足需求，我们期待进一步挖掘该药物的潜力，使其成为一款具有差异化优势的治疗方案。” Myosin抑制剂：梗阻性HCM患者“心”希望肥厚型心肌病（HCM）是一种以左心室肥厚为突出特征的原发性心肌病，是最常见的遗传性心脏病，也是青少年和运动员发生心脏性猝死的首要原因。根据“静息时或激发后左室流出道的峰值压差是否均<30mmHg”，肥厚型心肌病分为梗阻性（obstructive）与非梗阻性（non-obstructive）。与非梗阻性HCM患者相比，梗阻性HCM患者生存率更低，而缓解梗阻有助于降低死亡风险。目前，对于梗阻性HCM的治疗，心肌肌球蛋白抑制剂已获得《中国心肌病综合管理指南2025》IB类推荐。 HRS-1893是恒瑞医药自主研发的一种高选择性的Myosin小分子抑制剂，可特异性抑制心肌肌球蛋白ATP酶活性，使心肌收缩性能正常化，减少左心室肥厚并改善舒张期顺应。 HRS-1893 已开展多项临床试验，其Ⅰ期临床试验数据近期已在2025年欧洲心脏病学会（ESC）大会上公布。此外，该产品针对梗阻性肥厚型心肌病的治疗已启动III期临床。 Pharma ONE药物研发大数据平台显示，目前国内仅有一款（按通用名记）针对肥厚型梗阻性心肌病适应症的药物获批上市，即全球首创心肌肌球蛋白抑制剂玛伐凯泰（Mavacamten，商品名：迈凡妥），自2024年4月获批后即被迅速纳入国家医保目录。随着恒瑞HRS-1893III期临床的推进，肥厚型梗阻性心肌病的治疗格局或将迎来关键拐点。肥厚型梗阻性心肌病药物全球获批情况数据来源：Pharma ONE药物研发大数据平台结语从肿瘤到代谢，再到如今的心血管，恒瑞医药用一次又一次的海外授权证明：中国创新药不仅能“走出去”，更能“走得好”“走得远”。HRS-1893的出海，不仅给恒瑞带来丰厚财务回报，更为全球梗阻性肥厚型心肌病患者送去新的希望。 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

2025-09-05

·深蓝观

恒瑞能否撑起中国MNC的野心？

李昀 | 撰文又一 | 编辑 9 月 5 日，恒瑞医药宣布将 Myosin 抑制剂 HRS-1893 的大中华区外全球权益授权给美国公司 Braveheart Bio，首付款 6500 万美元，总金额最高可达 10 亿美元。这已经是恒瑞在半年内签下的第三笔大额出海 BD。恒润最近一段时间的表现，可谓春风得意。特别是在前段时期药企发布的一众中报中，公司也可以说一骑绝尘。首先来看大数字：2025年上半年，公司营业收入 157.61亿元，同比增长了15.88%；归母净利 44.50亿元，同比增长29.67%；经营现金流净额43.00亿元，同比增长41.80%——三项均创历年新高。创新药依然是公司的支柱业务。报告中提到，创新药销售及许可收入 95.61亿元，占比 60.66%，其中销售收入 75.70亿元——收入质量继续上了一个台阶。以瑞维鲁胺、达尔西利、恒格列净等医保内新品放量，叠加艾瑞昔布、瑞马唑仑、吡咯替尼、氟唑帕利等老品种扩适应证带来增量。对于恒瑞这名模范学生而言，这份报告可以算得上是正常发挥。但稳定的好成绩之余也有跳脱的地方。有业内人士指出，报告里净利增速显著快于营收，主要还是因为一次性大额授权首付款的贡献。“销售毛利率的提升相对有限。”他提到。“这也是很多国内药企都在面临的。所以虽然许多公司这次中报很好看，但在销售这一块，并没有太大改善。” 在中报里，有不小的篇幅集中体现公司的BD果实和预期：比如提到了与默沙东和IDEAYA的首付款已确认入账，期后事项中又有和GSK的大额合作。这也是公司首次把对外许可当成主营增长点来呈现。除了BD这一新节目以外，一些保留节目也略有变化。比如在市场方面，公司于今年年初启动了“筑渠工程”，打通慢病防治“最后一公里”，构建恒瑞全链条慢病生态体系。截至目前，公司社区终端覆盖已突破1500家，累计开展学术活动覆盖医生近2万人次。这一动作说明公司对慢病领域的重视。同时，在过去恒瑞的报表里，几乎不谈药店、DTP渠道，重点往往放在进医保或进医院。因此，这次中报的变化似乎也释放了一个信号：公司开始慢慢不再依赖院内销售，而是主动转向疾病“服务”的To C生态链。而在资本方面，公司披露H股募资103亿，并公告将回购10-20亿元的股份，用于实行新的员工持股计划，2025年激励规模不超过1400万股。这类具体的资本市场计划，在过去的恒瑞财报中并不常见。由此也可以看出，恒瑞正在越来越注重股东回报和国际投资人关系。在基本度过仿转创的艰难期后，恒瑞正在努力变成一个更“全面”的公司。这也让公司成为国内的其它biotech或pharma做了先行的榜样。但这个榜样是否真的立得住，依然需要更长时间的检验。 -01- 产品矩阵盘点 2025年上半年，公司共获批 6 款 1类创新药, 包括：注射用瑞卡西单抗、硫酸艾玛昔替尼片、瑞格列汀二甲双胍片 I/II、注射用瑞康曲妥珠单抗、苹果酸法米替尼胶囊、注射用磷罗拉匹坦帕洛诺司琼。另有 6 个新适应症获批，如硫酸艾玛昔替尼新增 3 个适应症，卡瑞利珠单抗联合法米替尼用于宫颈癌，夫那奇珠单抗、富马酸泰吉利定等新增适应症。以上这些产品决定了公司未来几年的业绩提升。其中，被外界比较看好的是法米替尼。这是一种小分子多靶点 VEGFR 抑制剂，与卡瑞利珠单抗联合已获批宫颈癌适应症。在去年的美国妇科肿瘤学会（SGO）年会上，恒瑞公布的临床数据显示：无论PD-L1表达如何，相较于卡瑞利珠单抗单药组和化疗组，卡瑞利珠单抗联合法米替尼组PFS均有显著获益。因为这种联合疗法可以覆盖多个瘤种，且与恒瑞现有产品形成组合优势，所以未来有希望作为公司一台重要引擎拓展到更多适应症上。除了今年的获批产品外，公司还有100+项创新产品正在临床开发，涵盖国内外共 400+ 项临床试验。报告期内：有5项上市申请受理中、10 项进入 III期、22 项进入 II 期、15 项进入 I 期。其中比较受关注的是SHR-2004和HRS-1893。前者是国内首个进入III期的FXI抑制剂，用以预防静脉血栓栓塞症，目前取得非劣结果，但在安全性上比临床对照组有明显优势；后者则是一款靶点为myosin的抑制剂，可以在针对肥厚型心肌病的靶向治疗种减少心脏过度收缩。从恒瑞的开发管线数量和进入I期后的管线数量来看，公司的大部分项目还处于临床前阶段。这也意味着，未来公司依然有一定余量的来实现早期资产BD。而在公司的已上市产品中，瑞维鲁胺、达尔西利、恒格列净这些医保内创新药由于精准覆盖未满足的临床需求，销额持续快速增长，成为推动收入超速增长的重要力量。阿帕替尼、硫培非格司亭、海曲泊帕虽未像前三款那样高频亮眼，但报告期内仍取得一定增长，可被看成为创新产品商业化正在铺开的代表。相对而言，公司的仿制药产品虽然卖得不错，但已经不再是公司的重心。布比卡因脂质体、注射用紫杉醇虽整体仿制药受集采压力影响，这类优质新品也能带动仿制产品整体微幅提升。 -02- 海外如何提速从公司这一年的动作来看，在资本运作和产品布局两个方面，公司都在快速推进国际化。今年5 月，对于恒瑞而言最大的事件当属成功在香港交易所上市，募资总额约 114 亿港元，成为近几年港股医药板块最大的一笔 IPO，正式开启 A+H 股双平台战略。这一举动，不仅仅是为了拿钱，更重要的是进一步增强品牌全球影响力与资本市场联通性，为后续国际化战略提供了“弹药”。这种战略最为人熟知的体现，就是公司形式各样的借船出海动作：有NewCo、传统BD、以及平台型BD。去年，公司宣布与国际基金公司在美国成立了一家合资公司Hercules，由恒瑞提供研发管线，基金方提供资金，这一思路引发了国内的“Newco”热潮。而今年，除了口服小分子药物HRS-5346和口服GnRH受体拮抗剂SHR7280的对外授权，公司还历史性地完成了和GSK潜在总金额约120亿美元的“打包式”合作。而除了会“卖”管线以外，公司的海外计划还包括自己卖产品。恒瑞在中报中披露，公司临床试验项目已覆盖全球超过 20 项海外试验，包括美国、欧洲、澳洲、日本、韩国等地区。这种全球化临床布局，意味着恒瑞正在从过去以中国为中心，逐步将研发与验证扩展到国际标准的监管体系，加快其产品在全球市场的注册与上市节奏。报告还提到，2025年上半年，公司多个产品都在进行欧盟MAA上市申报，卡瑞利珠单抗在美国的BLA重新上市申报也在与 FDA 积极沟通中。此外，公司还向FDA申请了瑞康曲妥珠单抗联合阿得贝利用于胃癌或胃食管结合部腺癌的孤儿药资格认证，并于近日获得FDA批准。这也意味着，和MNC的许可合作这是恒瑞海外战略的第一步。公司的长期目标，始终没有放弃自营海外产品。 -03- 风光下的隐患尽管在半年报上，恒瑞再一次展现了它的可靠。但一些异动还是让人产生了隐隐不对的感觉：据Wind统计，恒瑞医药的前十大股东中，有三家公司在第二季度进行了减持。对于这一现象，上述业内人士表示：这种减仓行为，大概率是阶段性的。“大部分机构，基本都认为恒瑞在长期战略没问题，甚至很优秀。但公司的短期兑现节奏因为一些动作会受限。” 比如，由于二季度市场普遍预期恒瑞会有大额 BD入账，所以公司业绩超预期的部分会在股价上提前反映。在密集出海之后，公司也许会在短期内进入一段时间的沉淀期。在这个窗口内，资本可以流动利用起来。同时，虽然公司创新药销售放量确实在进行，研发的“军火库”也依然很充实，但无法忽略国内竞争对手越来越多的事实。尤其是在恒瑞，管线大多数涉及热门靶点与适应症，公司fast follow的研发风格不太能支撑一款爆款药物的出现。从PD-1开始、虽然 PD-1 技术快速商业化带来了可观收入，但这种“跟跑”难以实现过去的时间差优势。PARP1抑制剂 HRS-1167、口服 GLP-1产品HRS-7535也是如此。而在其它热门领域如ADC，公司走的也是快速堆量路线。虽然目前已有约 12 款差异化 ADC 分子进入临床，4款进入三期，但并没有太多能独当一面的FIC或BIC产品。因此，在这个意义上而言，公司对大部分管线的平行线性推进，尤其适应目前BD为王的周期。但从历史的角度来看，虽然现在的MNC已经不过分执着打造“药王”，但几乎所有的MNC都受过一两款自家全球爆款药物的托举。如果恒瑞的目标依然是成为第一家中国MNC药企，那尽早从BD战略过渡至“研发-销售”的海外自营路线，将是公司近几年必须解决的课题。 ...... 欢迎添加作者交流：李昀：liyun9040820

财报引进/卖出并购

100 项与 HRS-7535 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床3期	中国	山东盛迪医药有限公司	2025-04-09
2型糖尿病	临床3期	中国	山东盛迪医药有限公司	2024-09-25
2型糖尿病肾脏病	临床2期	中国	山东盛迪医药有限公司	2024-06-17
糖尿病肾病	临床2期	-	山东盛迪医药有限公司	2024-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05759897 (ADA 12025 \| ADA 22025 \| NEWS) 人工标引	临床2期	2型糖尿病	194	HRS-7535 15mg	獵繭衊遞製鏇淵淵簾簾(遞夢廠願築獵鑰獵衊鑰) = 觸廠鬱積壓網糧壓餘齋餘艱齋壓壓蓋餘積顧簾 (窪簾遞艱蓋夢簾網鏇廠 ) 更多	积极	2025-06-20
				HRS-7535 30mg	獵繭衊遞製鏇淵淵簾簾(遞夢廠願築獵鑰獵衊鑰) = 願夢顧鹽醖製鹹艱膚襯餘艱齋壓壓蓋餘積顧簾 (窪簾遞艱蓋夢簾網鏇廠 ) 更多
ADA 12025 \| ADA 22025	临床2期	肥胖	235	HRS-7535 30 mgHRS-7535 30 mg	衊簾廠網廠衊壓壓獵範(鑰積遞蓋窪網窪餘窪壓) = 廠壓憲鏇鏇膚築壓繭鹹壓蓋積築窪鹽範鏇蓋衊 (憲顧顧艱網廠蓋積遞壓 ) 更多	积极	2025-06-20
				HRS-7535 60 mgHRS-7535 60 mg	衊簾廠網廠衊壓壓獵範(鑰積遞蓋窪網窪餘窪壓) = 壓夢鑰網築廠壓餘衊積壓蓋積築窪鹽範鏇蓋衊 (憲顧顧艱網廠蓋積遞壓 )
CTR20240369 (NEWS) 人工标引	临床2期	超重 \| 肥胖	235	HRS-7535 30mg	餘艱衊窪艱構觸積繭鹹(顧範衊衊淵遞繭鏇鹹鬱) = 鏇糧網鏇襯憲簾網範鑰築壓艱艱範繭鏇鏇觸鏇 (鏇簾鹹築選艱夢願鑰鑰 )	积极	2025-06-17
				HRS-7535 60mg	餘艱衊窪艱構觸積繭鹹(顧範衊衊淵遞繭鏇鹹鬱) = 製衊鹹鹽鑰餘窪鑰窪齋築壓艱艱範繭鏇鏇觸鏇 (鏇簾鹹築選艱夢願鑰鑰 )
NCT05347758 (EASD2023)	临床1期	-	24	HRS-7535 15 mg	觸鑰願鹹醖蓋願衊鬱憲(簾襯壓構糧構齋餘鏇繭) = Most common treatment-emergent adverse events in both SAD and MAD were nausea 構壓製襯獵觸廠窪遞餘 (憲衊鬱構齋鹽繭齋衊糧 ) 更多	积极	2023-10-03
				HRS-7535 60 mg
NCT05347758 (ADA 12023 \| ADA 22023) 人工标引	临床1期	-	48	HRS-7535 (SAD)	壓醖築鏇顧築鬱鹽醖淵(壓壓觸網憲網淵鑰遞範) = Most common treatment-emergent adverse events in both SAD and MAD were nausea and vomiting; all TEAEs were mild in severity. 膚襯膚構衊構醖觸憲鬱 (鑰觸襯範築繭艱壓積糧 ) 更多	积极	2023-06-20
				HRS-7535 (MAD)